Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

Trump Deploys National Guard Following Tornado Devastation in Arkansas

March 16, 2025

Trump Administration Warns Blue State Over Controversial High-Speed Rail Project

February 23, 2025

Trump Demands Impeachment of ‘Lunatic’ Judge

March 18, 2025

Asian Stocks Decline and U.S. Futures Fall Amid Ongoing Tariff Conflicts

April 6, 2025

Trump Advocates for Greenland Acquisition for ‘World Peace’ During Vance Visit

March 28, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • Health Experts Dismiss Claims Linking Tylenol to Autism
  • Verified Accounts Become New Target for Scammers Seeking Credibility
  • Harris Criticizes Major Newspapers for 2024 Endorsement Omission
  • Israel Destroys Evacuated Health Center in Gaza City, Reports Palestinian Medical Charity
  • White House Calls for Investigation into Trump’s UN Escalator Incident
  • Melih Gökçek Faces New Controversy Over Latest Banner
  • Louisville Factory Lays Off Immigrant Workers Following Status Revocation
  • Journalist Faces Disinformation Case After Report on Deportation Center Abuse
  • U.S. Secret Service Disrupts Telecom Network Threatening NYC During U.N. Assembly
  • Woman Sentenced to Over 4 Years for Attempting to Sell Graceland
  • Nexstar to Continue Preempting “Jimmy Kimmel Live!” After ABC Return
  • Trump Criticizes NATO Allies for Financing War with Russian Oil
  • Zelenskyy Responds to Trump’s Claim of Ukraine Regaining All Territory from Russia
  • Europe’s Work-Life Balance May Influence Trump’s H-1B Visa Changes
  • Powell Cites Slowing Labor Market for Rate Cut, Warns of Future Challenges
  • ABC Affiliates to Skip Nexstar and Sinclair’s Return Broadcasts
  • First Lady Launches Initiative to Enhance Online Safety for Children
  • Detention Officer in North Carolina Fired for Alleged Antifa Allegiance
  • Sarah Ferguson Cut Off by U.K. Charities Following Epstein Email Revelation
  • Travel Tips: Safeguarding Yourself from Fake Airline Wi-Fi Scams
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Wednesday, September 24
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Business » Moderna (MRNA) Q4 earnings 2024
Moderna (MRNA) Q4 earnings 2024

Moderna (MRNA) Q4 earnings 2024

News EditorBy News EditorFebruary 19, 2025 Business 5 Mins Read

Moderna has reported its fourth-quarter financial results for 2024, revealing a net loss that surpassed analyst expectations, despite revenue exceeding estimates. The biotech firm continues to grapple with a significant decrease in demand for its Covid-19 vaccine as it shifts focus toward new product development. The company aims to reduce costs further and anticipates more regulatory approvals for innovative treatments in the near future. Shares of Moderna saw an increase of over 3% on the day of the announcement.

Article Subheadings
1) Overview of Financial Performance
2) Cost-Cutting Measures and Future Expectations
3) Revenue Breakdown from Covid and RSV Vaccines
4) Pipeline of New Products and Approvals
5) Market Response and Future Outlook

Overview of Financial Performance

In its latest quarterly report, Moderna revealed a net loss of $1.12 billion for the fourth quarter of 2024, equivalent to losses of $2.91 per share. This is a steep decline from a net income of $217 million, or 55 cents per share, recorded in the same quarter of the previous year. Despite the substantial losses, the reported revenue of $966 million narrowly beat analyst expectations of $942.8 million, marking a significant decrease from the $2.8 billion generated during the corresponding period last year. The losses were characterized by a $238 million noncash charge linked to the termination of a contract manufacturing agreement, highlighting the ongoing challenges facing the organization as it transitions from a Covid-focused portfolio to broader therapeutic offerings.

Cost-Cutting Measures and Future Expectations

Looking ahead, Moderna’s Chief Financial Officer, Jamey Mock, noted that the company successfully achieved a 27% reduction in costs over the prior year and aims to further enhance its savings by $1 billion by the end of 2025. This turnaround strategy is essential as the company navigates declining Covid vaccine demand and a competitive landscape laden with pricing pressures and changes in government policies surrounding vaccinations. Moderna has reiterated its sales guidance for 2025, suggesting a projected revenue range of $1.5 billion to $2.5 billion, with the majority expected to arrive in the latter half of the year due to seasonal demand patterns for respiratory products.

Revenue Breakdown from Covid and RSV Vaccines

A significant portion of Moderna’s recent revenue was derived from its Covid-19 vaccine, which netted $923 million, representing a staggering 66% year-over-year decline. The U.S. sector accounted for $244 million, with international sales contributing $679 million. Analysts had predicted the Covid shot would generate $909 million, underscoring the shrinking market as vaccination rates decrease. Alongside the Covid vaccine, Moderna reported $15 million in sales from its newly-approved respiratory syncytial virus (RSV) vaccine targeted at adults over the age of 60, which began its rollout after receiving FDA clearance.

Pipeline of New Products and Approvals

Moderna’s future plans hinge on expanding its product pipeline, which leverages its messenger RNA technology. The company aims to secure approval for ten new products over the next three years. Currently, three mRNA products have been submitted for regulatory approval, including a next-generation covid vaccine and a combination shot addressing both Covid and flu viruses. The FDA is expected to issue a decision on the next-generation Covid vaccine by May, with further developments anticipated for the RSV shot in June. Additional projects include a stand-alone flu vaccine and a personalized cancer treatment in collaboration with Merck, as well as products targeting latent viruses.

Market Response and Future Outlook

Despite the initial negative market sentiment resulting from Moderna’s cut to its sales guidance earlier in the year, which caused shares to drop by more than 20%, the company’s stock rose by more than 3% following the latest earnings report. While headwinds remain—such as increased competition in the Covid vaccine arena and uncertain advisory recommendations regarding respiratory syncytial virus vaccination—the company remains optimistic about counteracting these challenges and returning to a growth trajectory. Continued market engagement and innovative product development will be crucial for Moderna as it transitions from pandemic-era revenue sources to a more diversified pharmaceutical portfolio.

No. Key Points
1 Moderna reported a net loss of $1.12 billion for Q4 2024.
2 Revenue exceeded expectations at $966 million, but was less than half of $2.8 billion from a year ago.
3 Moderna aims to reduce costs by an additional $1 billion by 2025.
4 The Covid vaccine generated $923 million in revenue, down 66% from the previous year.
5 Moderna plans to launch ten new products over the next three years based on mRNA technology.

Summary

Moderna’s recent financial results underscore the challenges the company faces as it adapts to a post-Covid world. Despite a significant net loss and declining vaccine sales, the company’s proactive cost-cutting measures and commitment to innovation suggest a strategic pivot toward a more diversified pharmaceutical future. The upcoming regulatory decisions on new products will be critical as Moderna strives to regain momentum and establish a sustainable growth path post-pandemic.

Frequently Asked Questions

Question: Why did Moderna report significant losses in Q4 2024?

Moderna experienced a net loss largely due to reduced sales from its Covid-19 vaccine, as demand has significantly declined. Additionally, the company faced a noncash charge impacting financial performance.

Question: What strategies is Moderna employing to reduce costs?

The company successfully reduced costs by 27% compared to the previous year and aims to cut another $1 billion in costs by the end of 2025 through various operational efficiencies.

Question: What is next for Moderna’s product development?

Moderna plans to expand its product lineup with ten new approvals over the next three years, focusing on mRNA technology to develop vaccines and treatments for respiratory diseases and other conditions.

Business Ethics Business Growth Business News Business Technology Consumer Trends Corporate Finance Corporate Strategy earnings Economic Outlook Entrepreneurship Global Business Innovation Investment Opportunities Leadership Management Market Trends Mergers & Acquisitions Moderna MRNA Retail Business Small Business Startups Supply Chain
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Business

ABC Affiliates to Skip Nexstar and Sinclair’s Return Broadcasts

5 Mins Read
Business

Jimmy Kimmel Live Returns to ABC on Tuesday

4 Mins Read
Business

Walmart Marketplace Faces Surge in Counterfeits and Scams Amid Rapid Growth

6 Mins Read
Business

Warehouse Clubs Expand Presence with New Stores and Membership Growth

7 Mins Read
Business

Trump Threatens Broadcast Station Licenses Amid Regulatory Debates

6 Mins Read
Business

FedEx Reports Q1 2026 Earnings Results

4 Mins Read
Journalism Under Siege
Editors Picks

Judge Affirms Musk’s Ongoing Leadership Role in DOGE

May 28, 2025

Daughter of Mutilated Dissident Urges Trump to Halt Nuclear Talks with Iran

April 13, 2025

Elon Musk Launches New Political Party

July 5, 2025

Trump to Return to Michigan Next Week for First Post-Election Visit

April 24, 2025

Trump Nominee Linda McMahon Moves to Final Senate Vote

February 27, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
Go to mobile version